Drug name: CBT-15


Related CSCTT Targets

DCLK1 [ref.1]

CBT-15

Cas.no PubChem ID
Introduction

Reference

  • [1] Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
    Int J Cancer. 2018 Sep 1;143(5):1162-1175. [ 29577277 ]

Back to top